

GEOVAX LABS, INC.
Condensed Consolidated Statements of Operations Information
(amounts in thousands, except common share information)

	Year Ended December 31,	
	2023	2022
Grant revenue	\$ -	\$ 81
Operating expenses:		
Research and development	20,721	9,123
General and administrative	6,022	4,987
	26,743	14,110
Loss from operations	(26,743)	(14,029)
Other income (expense), net	776	7
Net loss	\$ (25,967)	\$ (14,021)
Net loss per common share	\$ (14.29)	\$ (12.39)
Weighted averages shares outstanding	1,817,282	1,131,546

Condensed Consolidated Balance Sheet Information
(amounts in thousands, except common share information)

	December 31,	
	2023	2022
Assets		
Cash and cash equivalents	\$ 6,453	\$ 27,613
Other current assets	1,433	1,326
Total current assets	7,886	28,939
Property and other assets	1,397	2,409
Total assets	\$ 9,283	\$ 31,348
Liabilities and stockholders' equity		
Total liabilities	\$ 3,520	\$ 4,748
Stockholders' equity	5,763	26,600
Total liabilities and stockholders' equity	\$ 9,283	\$ 31,348
Common shares outstanding	1,977,152	1,755,664